Cymbalta's Expanded GAD Claim Is A Load Off Lilly's Mind
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval for maintenance treatment of generalized anxiety disorder may be more about shoring up the blockbuster drug than creating a market for growth.